STOK — Stoke Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $620.26m
- $418.87m
- $8.78m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 12.4 | 8.78 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 35.7 | 53 | 86.1 | 117 | 124 |
Operating Profit | -35.7 | -53 | -86.1 | -104 | -115 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -32.3 | -52.2 | -85.8 | -101 | -105 |
Net Income After Taxes | -32.3 | -52.2 | -85.8 | -101 | -105 |
Net Income Before Extraordinary Items | |||||
Net Income | -32.3 | -52.2 | -85.8 | -101 | -105 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -32.3 | -52.2 | -85.8 | -101 | -105 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.07 | -1.56 | -2.34 | -2.6 | -2.38 |